tbuckley/cabot-search huggingface dataset:
Management of elderly lung cancer patients in France: A national prospective survey by the French Intergroup of thoracic Oncology (IFCT)
Authors: M. P. Lebitasy, I. Monnet, A. Depierre, P. Girard, H. Berard, P. Fournel, F. Vaylet, A. Rivière, P. Bombaron, E. Quoix
Journal: Journal of Clinical Oncology (2004)

8163 Background. Thirty percent of lung cancer patients (pts) are 70 or older at diagnosis. However their representation in clinical trials is by far below and their management mostly unknown.We present here a survey about the management and determinants of survival of elderly lung cancer pts in France. Methods. Age categories (AC)(70–74, 75–80, 81–84, 85 and older), sex, social status, smoking habits, performance status (PS), comorbidities, histology, stage and treatment were studied. Results. From sept 02 to oct 03, 1540 pts were included by 77 centers. Data are available for 1000 pts. Median age was 76 (70–96). 810 were males (81%). 77% of males were married, 14% widowed (respectively 40% and 46.3% of females, p<.0001), these figures being similar to the general population statistics. 94.8% of the pts lived at home, the % decreasing from 98% to 87.1% with AC (p=.004). PS was 0 or 1 in 54.4%, >=2 in 44.8%. There was a trend towards a better PS in females (p = .056) and a significantly worst with increased AC. Histology was in 40.5% squamous cell, 15.5% small cell, 29% adenocarcinoma, 11.6% large cell. 52.6% of pts had a history of COPD, 37% hypertension, 18.6% ischaemic heart disease, 17.6 lower limb arteritis, 14.2% diabetes, 7.7% stroke. 857 were smokers or ex-smokers. There were more non-smokers in females (48% versus 2.7%, p<.0001). Also the % of non-smokers increased with AC from 6.4% to 40%. Bronchoscopy was performed in 96% of pts with positive biopsies in 60%. TTNA was performed in 20% of pts and positive in 18%. Imaging procedures were abdominal US in 60%, adrenal CT scan in 87%, brain CT in 79.5%, bone scan in 41%. 43.7% of NSCLC pts were metastatic and 72.3% SCLC pts. Treatment was only symptomatic in 16% with increasing frequency across the AC. Surgical resection was performed in 20%, mediastinal irradiation in 20.5% and chemotherapy in 70.7%. At 3-month follow-up available for 880 pts, 271 had died. Conclusions. Diagnostic procedures in elderly do not differ from that of younger pts. The % of symptomatic treatment only is higher and increasing with AC. Early death is not an infrequent feature probably rather explained by comorbidities than by PS. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration National Committee Against Respiratory Diseases; Bristol-Myers Squibb
RVOT-VTI/PASP: A NOVEL NON-INVASIVE METRIC OF PULMONARY ARTERIAL COMPLIANCE AND DIASTOLIC PRESSURE GRADIENT STATUS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
Authors: Frances Mao, Priyanka T. Bhattacharya, Gregory S. Troutman, Jonathan N. Menachem, Monique Tanna, Arieh L. Fox, Edo Y. Birati, Paul Forfia, Anjali Vaidya, Jeremy Mazurek
Journal: Journal of the American College of Cardiology (2017)
RHYTHM ABNORMALITIES IN CHILDREN AND YOUNG ADULTS WITH MARFAN SYNDROME
Authors: Douglas Mah, Lynn Sleeper, Jane Crosson, Richard Czosek, David Gamboa, Barry Love, Brian McCrindle, Laura Muino Mosquero, Aaron Olson, Maully Shah, Stephanie Wechsler, Luciana Young, Ronald Lacro
Journal: Journal of the American College of Cardiology (2017)
Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience
Authors: Ying S Zou, Yi Huang, Zhou Feng, Sin Chan, Shweta Shukla, Ina Lee, Zeba Singh, Mehmet H. Kocoglu, Aaron P. Rapoport, Ning Ma, Nancy M. Hardy, Jean Yared, Maria R Baer, Ashraf Z Badros
Journal: Blood (2015)
CLINICAL OUTCOMES AFTER IMPLANTATION OF ABSORB BVS IN A REAL WORLD SETTING, WITH PRE- AND POST-DILATATION, GUIDED BY INTRAVASCULAR ULTRASOUND &amp; OPTICAL COHERENCE TOMOGRAPHY
Authors: Costantino R. Costantini, Sergio Tarbine, Costantino O. Costantini, Marcelo Freitas, Daniel A. Zanuttini, Marcos Denk
Journal: Journal of the American College of Cardiology (2017)
Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation
Authors: Elias J. Jabbour, Jorge E. Cortes, Moshe Talpaz, Michele Baccarani, Michael J. Mauro, Andreas Hochhaus, Timothy P. Hughes, Francois Guilhot, Michael W. Deininger, Neil Shah, Dale L. Bixby, Ian W. Flinn, Thomas O'Hare, Stephanie Lustgarten, Victor M. Rivera, Sergio Santillana, Hagop M. Kantarjian
Journal: Blood (2016)
Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease
Authors: Wan-Chuan Tsai, Hon-Yen Wu, Yu-Sen Peng, Ju-Yeh Yang, Hung-Yuan Chen, Yen-Ling Chiu, Shih-Ping Hsu, Mei-Ju Ko, Mei-Fen Pai, Yu-Kang Tu, Kuan-Yu Hung, Kuo-Liong Chien
Journal: JAMA Internal Medicine (2017)

The optimal blood pressure (BP) target remains debated in nondiabetic patients with chronic kidney disease (CKD).To compare intensive BP control (<130/80 mm Hg) with standard BP control (<140/90 mm Hg) on major renal outcomes in patients with CKD without diabetes.Searches of PubMed, MEDLINE, Embase, and Cochrane Library for publications up to March 24, 2016.Randomized clinical trials that compared an intensive vs a standard BP target in nondiabetic adults with CKD, reporting changes in glomerular filtration rate (GFR), doubling of serum creatinine level, 50% reduction in GFR, end-stage renal disease (ESRD), or all-cause mortality.Random-effects meta-analyses for pooling effect measures. Meta-regression and subgroup analyses for exploring heterogeneity.Differences in annual rate of change in GFR were expressed as mean differences with 95% CIs. Differences in doubling of serum creatinine or 50% reduction in GFR, ESRD, composite renal outcome, and all-cause mortality were expressed as risk ratios (RRs) with 95% CIs.We identified 9 trials with 8127 patients and a median follow-up of 3.3 years. Compared with standard BP control, intensive BP control did not show a significant difference on the annual rate of change in GFR (mean difference, 0.07; 95% CI, -0.16 to 0.29 mL/min/1.73 m2/y), doubling of serum creatinine level or 50% reduction in GFR (RR, 0.99; 95% CI, 0.76-1.29), ESRD (RR, 0.96; 95% CI, 0.78-1.18), composite renal outcome (RR, 0.99; 95% CI, 0.81-1.21), or all-cause mortality (RR, 0.95; 95% CI, 0.66-1.37). Nonblacks and patients with higher levels of proteinuria showed a trend of lower risk of kidney disease progression with intensive BP control.Targeting BP below the current standard did not provide additional benefit for renal outcomes compared with standard treatment during a follow-up of 3.3 years in patients with CKD without diabetes. However, nonblack patients or those with higher levels of proteinuria might benefit from the intensive BP-lowering treatments.
SUBCLINICAL ATHEROSCLEROSIS IN THE ABSENCE OF CARDIOVASCULAR RISK FACTORS: PRE-RISK STATUS IN THE PESA (PROGRESSION OF EARLY SUBCLINICAL ATHEROSCLEROSIS) STUDY
Authors: Leticia Fernandez-Friera, Lopez-Melgar Beatriz, Belen Oliva, Agustin Mocoroa, Jose Maria Mendiguren, Stuart Pocock, Borja Ibañez, Jose Manuel Garcia-Ruiz, Antonio Fernandez-Ortiz, Javier Sanz, Valentin Fuster
Journal: Journal of the American College of Cardiology (2017)
The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.
Authors: Hani Hassoun, Lilian Reich, Virginia M. Klimek, Madhav Dhodapkar, Adam Cohen, Tarun Kewalramani, Elyn R. Riedel, Cyrus V. Hedvat, Julie Teruya-Feldstein, Daniel A. Filippa, Martin Fleisher, Stephen D. Nimer, Raymond L. Comenzo
Journal: Blood (2005)
CHADS2 AND CHA2DS2VASC SCORES AS PREDICTORS OF LENGTH OF STAY AND COST OF CARE IN HOSPITALISED ATRIAL FIBRILLATION PATIENTS: INSIGHTS FROM A NATIONAL DATABASE
Authors: Sopan Lahewala, Shilpkumar Arora, Prashant Patel, Harshil Shah, Byomesh Tripathi, Nilay Patel, Chirag Savani, Rajvee Patel, Ambarish Pathak, Kosha Thakore, Abhishek Deshmukh
Journal: Journal of the American College of Cardiology (2017)
HYALURONIC ACID, HYALURONIDASE-2 AND ACUTE CORONARY SYNDROMES: POSSIBLE CORRELATION WITH PLAQUE EROSION
Authors: Daniela Pedicino, Ramona Vinci, Giglio Ada Francesca, Francesco Trotta, Davide Flego, Giulia Angelini, Claudia Lucci, Aureliano Ruggio, Antonio Iaconelli, Domenico Galante, Anna Severino, Luigi Biasucci, Giovanna Liuzzo, Filippo Crea
Journal: Journal of the American College of Cardiology (2017)
IMPAIRED FASTING GLUCOSE IS THE MAJOR DETERMINANT OF THE 20-YEAR MORTALITY RISK ASSOCIATED WITH METABOLIC SYNDROME IN NON-DIABETIC PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Authors: Arwa Younis, Ilan Goldenberg, Boaz Tzur, Anna Mazu, Anan Younis, Zvi Fisman, Alexander Tannenbaum, Robert Klempfner
Journal: Journal of the American College of Cardiology (2017)
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models.
Authors: Roberto Bianco, Roberta Rosa, Lucia Nappi, Luigi Formisano, Vincenzo Damiano, Claudia d'Amato, Ana Paula de Maio, Roberta Marciano, Umberto Malapelle, Giancarlo Troncone, Chiara Carlomagno, Alfonso De Stefano, Giampaolo Tortora, Sabino De Placido
Journal: Journal of Clinical Oncology (2012)

e13509 Background: Although EGFR inhibitors, such as the mAb cetuximab, represent an effective strategy in colorectal cancer (CRC), the clinical use of these agents is limited by intrinsic or acquired resistance. Alterations in the ‘sphingolipid rheostat’, or the balance between the proapoptotic molecule ceramide and the mitogenic factor sphingosine-1-phosphate (S1P), due to overactivation of sphingosine kinase 1 (SphK1), have been involved in the regulation of resistance to anticancer agents. Since some studies described cross-talks between SphK1 and EGFR-dependent signalling pathways, we investigated the contribution of SphK1 to cetuximab resistance in CRC models. Methods: We used CRC cell lines with both intrinsic or acquired resistance to cetuximab. In these models, we analyzed SphK1 expression/activation by using different tools, including the available drug fingolimod (FTY720), both in vitro and in vivo. We confirmed our data through a tissue microarray (TMA)-based analysis on CRC tissues. Results: SphK1 is overexpressed in CRC cells resistant to cetuximab. Higher doses of N,N-dimethylsphingosine (DMS), a potent competitive inhibitor of SphK1, are needed to achieve complete enzyme saturation and survival inhibition in resistant cells. Moreover, ceramide induces apoptosis less efficiently in resistant than in sensitive cells, consistently with the idea that increased SphK1 levels mediate S1P synthesis by ceramide in resistant cells. SphK1 contribution to resistance is supported by the demonstration that SphK1 inhibition by DMS or silencing via siRNA in resistant cells restores sensitivity to cetuximab, whereas exogenous SphK1 overexpression in wild-type cells confers resistance. Re-sensitization to cetuximab is observed after treatment with fingolimod, a S1P receptor inhibitor, both in vitro and in nude mice xenografted with CRC cells. Finally, a TMA-based analysis on CRC tissues revealed that SphK1 expression is related to K-Ras mutational status, a well-known determinant of cetuximab resistance. Conclusions: Our data could clarify the role of SphK1 in the onset of resistance to cetuximab, thus suggesting SphK1 inhibition as a part of novel targeting strategies for resistant cancer patients.
COMPARATIVE OUTCOME OF PARAVALVULAR LEAK FOLLOWING SURGICAL VERSUS TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Mahmoud Ali, Ratnasari Padang, Kevin Greason, Christopher Scott, Charanjit Rihal, Mackram Eleid, Patricia Pellikka, Vuyisile Nkomo, Sorin Pislaru
Journal: Journal of the American College of Cardiology (2017)
A cost-effectiveness analysis of surveillance, radiotherapy, and carboplatin in the management of stage I testicular seminoma
Authors: S. J. Patrice, J. R. Patrice, J. S. Steinberg, A. L. Zietman, M. R. Smith, J. A. Hayman
Journal: Journal of Clinical Oncology (2006)

6108 Background: Alternative post-orchiectomy management strategies for patients with Stage I Testicular Seminoma (TS) have different costs, recurrence risks, and toxicities. This study compares the cost-effectiveness (CE) of surveillance (SVL), dogleg radiotherapy (DLRT), para-aortic radiotherapy (PART), or one cycle of Carboplatin (CARB) from a societal perspective. Methods: Using TreeAge software, a decision tree with embedded Markov process models was constructed to simulate the natural history of Stage I TS from orchiectomy until death for hypothetical cohorts of 35 year-old men. Recurrence risks, established follow-up guidelines, utilities, direct and indirect costs, and excess mortality and costs attributable to late second cancers were modeled. CE and incremental CE (ICER) ratios were calculated per life-year (LY) and quality-adjusted life year (QALY) using a 3% discount rate; one- and two- way sensitivity analyses were performed. Results: The base case results are shown in the Table . SVL is CE when both recurrence risk is decreased 50% and follow-up costs are reduced 65%. PART is CE when follow-up and indirect costs are reduced 29% while PART second cancer relative risk (RR) is reduced to 1.8. CARB is CE when follow-up and indirect costs are reduced 41%, or the PART relapse risk function is increased 41% while DLRT costs are increased 87%. The model was insensitive to changes in utilities. Conclusions: Despite an assumed increased second cancer risk, DLRT is CE. This is due to the routine use of intensive follow-up for the alternative strategies and the high cost of salvage treatment. PART may become CE if a decrease in second cancer RR is observed without increases in recurrences. SVL should be reserved for those with favorable prognostic factors who can be followed less intensely. At a reasonable willingness-to-pay ceiling CARB is optimal, however, the small differences in effectiveness between the strategies may support decision-making based on costs. [Table: see text] No significant financial relationships to disclose.
HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression.
Authors: Serena Di Cosimo, Danila Serpico, Luca Porcu, Anna Tessari, Leonardo Molino, Valter Torri, Filippo de Braud
Journal: Journal of Clinical Oncology (2014)

e11591 Background: Few reports in the literature give detailed figures on metastatic patterns in HER2+ MBC. This study reports a detailed analysis of MBC patients (pts) presentation, the development of metastases (met) and the factors influencing them. Methods: We analyzed an institutional database containing the treatment history of pts who received at least one trastuzumab-based regimen for HER2+ MBC. A logistic regression model was used to estimate the risk of progression (RP) in a given site based on the number of prior progression events in that site. The proportion of metastatic sites and the hazard ratio (HR) for each site respect to age, disease free-interval, hormone-receptor (ER), type of therapy were estimated by treatment line. I2was used to evaluate the heterogeneity across treatment lines. The HR of the cumulative incidence function was considered because of competing metastatic sites. Results: A total of112 pts were analysed. The median age was 50 (range 26 – 74) years; 16% were metastatic at debut, 71% presented with ER+. Localization of met in visceral sites (49%, I2=5%), soft tissue (41%, I2=0%), brain (16%, I2=0%), and bone (29%, I2=20%) was consistent across all lines of therapy. Having a given site affected by met was a major risk factor of progression in that site, i.e. visceral (OR= 1.9, CI 1.7-2, p <0.0001), soft tissue (OR=1.5, CI 1.4-1.6, p= <0.0001), bone (OR=1.8, CI 1.6-2, p<0.0001), and brain (OR=4.2, CI 3.1-5.6, p <0.0001). After adjusting for this, we found a trend towards decreased progression in brain with increasing age (HR= 0.73, CI 0.53-1.02, p=0.07; I2=22%), and increased progression in bone for ER+ pts (HR= 1.88, CI 0.97- 3.64, p=0.06; I2=0%) across all treatment lines. Of note, a reduced risk for bone progression was observed in pts receiving anti-HER2 (HR= 0.66; CI 0.45-0.98; p=0.04), but the heterogeneity in the regimens prescribed precluded analyses of specific therapies with outcome. Conclusions: Risk factors for progression in HER2+ MBC do not differ between patterns of spreading. Nevertheless, young and ER+ MBC pts are more likely to develop brain and bone met as compared to the rest. Current treatments seem unlikely to affect the pattern of progression, with the unique exception of bone met.
RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
Authors: Flavia Pichiorri, Sung-Suk Suh, Alberto Rocci, Luciana De Luca, Cristian Taccioli, Ramasamy Santhanam, Wenchao Zhou, Don M. Benson, Craig Hofmainster, Hansjuerg Alder, Michela Garofalo, Gianpiero Di Leva, Stefano Volinia, Huey-Jen Lin, Danilo Perrotti, Michael Kuehl, Rami I. Aqeilan, Antonio Palumbo, Carlo M. Croce
Journal: Cancer Cell (2016)
Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005
Authors: Theresa Hahn, Philip L. McCarthy, Anna Hassebroek, John P. Klein, J. Douglas Rizzo, Susan Parsons, Steven Joffe, Navneet S. Majhail
Journal: Blood (2010)
THE EFFECT OF BODY MASS INDEX ON PROCEDURAL EFFICACY IN TRANSFEMORAL VERSUS TRANSRADIAL CORONARY ANGIOGRAPHY
Authors: Amornpol Anuwatworn, Alexander Pham, Shenjing Li, Jimmy Yee, Vishesh Kumar, James Higgins, Terezia Petraskova, Julia Stys, Paul Thompson, Adam Stys, Tomasz Stys
Journal: Journal of the American College of Cardiology (2017)
Double KRAS and BRAF mutations in colorectal cancer in a single oncologic department series.
Authors: Pamela Francesca Guglielmini, Maura Rossi, Federica Grosso, Sara Orecchia, Marco Galliano, Elisa Bennicelli, Silvia Zai, Vittorio Fusco, Roberta Libener, Narciso Mariani, Giuseppe Spinoglio, Pierluigi Piovano
Journal: Journal of Clinical Oncology (2013)

e14657 Background: KRAS and BRAF mutations have prognostic and predictive value in colorectal cancer and are predominantly mutually exclusive. Only a few cases of double mutations (DM) have been reported so far but the actual incidence and presumed role in worsening prognosis is still unknown. Here we report on a series of KRAS and BRAF mutations, focusing on three cases of KRAS and BRAF DM. Methods: since May 2010, 316 consecutive colorectal cancer samples were collected by our Oncology Department; ten patients (3%) had high risk localized disease and 306 (97%) metastatic disease. Genome DNA from formalin-fixed paraffin embedded samples with tumor cells &gt; 50% was analyzed by reverse dot blot with KRAS-BRAF StripAssay kit (Nuclear Laser Medicine). Results: KRAS point mutations were found in 141 patients (44.6%): 32% G12V, 30.5% G12D, 14.9% G13D, 6.4% G12S, 5.7% G12C, 4.9% G12A, 4.9% G12R, 0.7% G13C; V600E BRAF point mutation was found in 21 patients (6.6%). Three patients (1%) displayed DM: 2 KRAS G13D + BRAF V600E (A and B) and 1 KRAS G12V + BRAF V600E (C). Patients A and C, both aged 59, presented with metastatic disease. Patient A had a rectal primary, a single lung lesion and mediastinal nodes. He failed first line FOLFOX4 plus bevacizumab and underwent salvage surgery both on primary and metastatic disease. He relapsed in 3 months with liver and brain metastasis and died after one year from diagnosis. Patient B had huge liver lesions at presentation. She progressed after 3 courses of FOLFIRI and died after 6 months from diagnosis. Patient C was operated on for a right colon cancer, G3, pT2N2, stage IIIB with lymph vascular invasion and had adjuvant FOLFOX 4. The 6-month assessment did not show relapse. Conclusions: in our series KRAS mutation incidence was in line with literature, but G12V was far more frequent. KRAS-BRAF DM accounted for 1% of all cases and the 2 patients with metastatic disease had an aggressive course with a much lower than expected survival. To our knowledge no series of DM have been described, hindering the understanding of their biological meaning. According to our experience, metastatic double mutated patients do not respond to standard therapy and should be treated with new drugs combinations in clinical trials.
Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC).
Authors: Amanda Psyrri, Ju-Whei Lee, Eirini Pectasides, Maria Vassilakopoulou, Barbara Burtness, David Rimm, Harold J. Wanebo, Arlene A. Forastiere
Journal: Journal of Clinical Oncology (2012)

5576 Background: Theidentification of resistance mechanisms to Epidermal Growth Factor Receptor (EGFR) inhibitors remains critical lack in the management of HNSCC. We sought to determine predictors for response to cetuximab in a phase II clinical trial. Methods: 63 patients (pts) with operable stage III/IV HNSCC participated in E2303, an Eastern Cooperative Oncology Group (ECOG) phase II trial of induction chemotherapy with weekly cetuximab, paclitaxel and carboplatin x 6 followed by chemoradiotherapy with the same regimen. A tissue microarray was constructed and EGFR, ERK1/2, Met, pAkt and STAT protein expression levels were assessed using AQUA. The objectives of analysis were to determine association of biomarkers with E2303 efficacy outcomes (best objective response (OR), overall survival (OS), progression-free survival (PFS), and event-free survival (EFS)). The logistic regression model was used to examine relationship between marker measurements (on a continuous scale) and OR. The univariate and multivariate Cox proportional hazards models were used to evaluate the relationship between markers and event-time distributions. Fisher’s exact test was used to evaluate differences in response rate between groups (high vs. low AQUA scores). Event-time distributions were estimated by the Kaplan-Meier method and compared by the log-rank test. Results: Cytoplasmic ERK1/2 levels weresignificantly associated with PFS and OS (p=0.03 and 0.01, respectively). Nuclear ERK1/2 levels were significantly associated with OS (p=0.02) and tended towards significance for PFS (p=0.09). The multivariate Cox regression analysis shows that cytoplasmic and nuclear ERK1/2 are significantly associated with OS and PFS after controlling for primary site and disease stage, respectively There was no significant association between cytoplasmic or nuclear ERK1/2 status and OR (p-values 0.98 and 0.41, respectively).No association was found between expression of any of other biomarkers and outcome measures. Our data analysis was based on 35 pts with marker data available. Conclusions: Ras/MAPK/ERKpathway may be associated with resistance to cetuximab in HNSCC.
USE OF AN ESOPHAGEAL RETRACTOR TO PREVENT THERMAL INJURIES DURING ATRIAL FIBRILLATION ABLATION: A MULTI-CENTER EXPERIENCE
Authors: Valay Parikh, Madhav Lavu, Mohammad-Ali Jazayeri, Venkat Lakshmi Kishan Vuddanda, Sudharani Bommana, Donita Atkins, Mitra Mohanty, Luigi Di Biase, Raghuveer Dendi, Akash Makkar, Vijay Swarup, Andrea Natale, Madhu Reddy, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2017)